With funding from charity Kidney Research UK, Dr Carl May from Bristol Medical School and his team have identified a new treatment pathway for patients with non-genetic (idiopathic) nephrotic syndrome ...
Neutrophil gelatinase-associated lipocalin (NGAL), a biomarker released in response to tubular injury, may serve as a noninvasive tool for measuring kidney injury. A new systematic review and ...
Patients with nephrotic syndrome were far more likely than healthy controls to suffer end-stage kidney disease, particularly if they had focal segmental glomerulosclerosis or membranous nephropathy.
DelveInsight's comprehensive analysis reveals the Nephrotic Syndrome therapeutics market reached USD 401 million in 2022 across the 7MM, with emerging therapies including FDA-approved Furoscix and ...
The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...
DelveInsight’s “Nephrotic Syndrome Pipeline Insight 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in the Nephrotic Syndrome pipeline landscape. It covers the ...
In a small study, proteinuria improved even in patients with nephrotic syndrome and lupus nephritis. Belimumab appears similarly effective and well tolerated in patients with lupus nephritis (LN) with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback